

Dab/Tram (dabrafenib and trametinib)

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



More serious and disabling adverse events observed



Other adjustments



Dab/Tram (dabrafenib and trametinib)

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Advanced NSCLC with a BRAF V600 mutation

Experimental Arm: Dab/Tram (dabrafenib and trametinib)

Control Arm: Single arm



